Chris Liddle

1.5k total citations
16 papers, 1.2k citations indexed

About

Chris Liddle is a scholar working on Epidemiology, Molecular Biology and Oncology. According to data from OpenAlex, Chris Liddle has authored 16 papers receiving a total of 1.2k indexed citations (citations by other indexed papers that have themselves been cited), including 7 papers in Epidemiology, 5 papers in Molecular Biology and 5 papers in Oncology. Recurrent topics in Chris Liddle's work include Liver Disease Diagnosis and Treatment (7 papers), Drug Transport and Resistance Mechanisms (3 papers) and Cancer therapeutics and mechanisms (3 papers). Chris Liddle is often cited by papers focused on Liver Disease Diagnosis and Treatment (7 papers), Drug Transport and Resistance Mechanisms (3 papers) and Cancer therapeutics and mechanisms (3 papers). Chris Liddle collaborates with scholars based in Australia, New Zealand and United Kingdom. Chris Liddle's co-authors include GC Farrell, Alistair Stewart, Prakash Mistry, Wendy Dangerfield, Peter Charlton, Douglas Bootle, Jane A. Plumb, David J. Templeton, Rita Lin and Dev Samarasinghe and has published in prestigious journals such as Journal of Clinical Oncology, Gastroenterology and Hepatology.

In The Last Decade

Chris Liddle

16 papers receiving 1.2k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Chris Liddle Australia	14	531	371	338	253	169	16	1.2k
Chang-Fang Chiu Taiwan	26	344 0.6×	873 2.4×	430 1.3×	202 0.8×	57 0.3×	67	1.9k
Klaus Kutz Switzerland	21	292 0.5×	297 0.8×	304 0.9×	74 0.3×	178 1.1×	59	1.8k
Kung‐Kai Kuo Taiwan	22	318 0.6×	508 1.4×	317 0.9×	136 0.5×	128 0.8×	70	1.5k
G Babany France	21	405 0.8×	119 0.3×	220 0.7×	460 1.8×	58 0.3×	56	1.3k
Pankaj Patel India	20	549 1.0×	535 1.4×	106 0.3×	155 0.6×	302 1.8×	108	1.7k
Patrick Caron Canada	30	348 0.7×	778 2.1×	770 2.3×	168 0.7×	336 2.0×	80	2.4k
S Matern Germany	23	172 0.3×	286 0.8×	560 1.7×	102 0.4×	56 0.3×	84	1.5k
Markus Keiser Germany	21	252 0.5×	185 0.5×	626 1.9×	209 0.8×	58 0.3×	36	1.3k
Hao Jin China	22	171 0.3×	303 0.8×	207 0.6×	173 0.7×	174 1.0×	90	1.3k
Gondi Kumar United States	24	137 0.3×	788 2.1×	894 2.6×	129 0.5×	45 0.3×	53	2.5k

Countries citing papers authored by Chris Liddle

Since Specialization

Citations

This map shows the geographic impact of Chris Liddle's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Chris Liddle with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Chris Liddle more than expected).

Fields of papers citing papers by Chris Liddle

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Chris Liddle. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Chris Liddle. The network helps show where Chris Liddle may publish in the future.

Co-authorship network of co-authors of Chris Liddle

This figure shows the co-authorship network connecting the top 25 collaborators of Chris Liddle. A scholar is included among the top collaborators of Chris Liddle based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Chris Liddle. Chris Liddle is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

16 of 16 papers shown

Adams, Leon A., Zhengyi Wang, Chris Liddle, et al.. (2020). Bile acids associate with specific gut microbiota, low‐level alcohol consumption and liver fibrosis in patients with non‐alcoholic fatty liver disease. Liver International. 40(6). 1356–1365. 62 indexed citations

Bullock, Martyn, Cheng Li, In Ho Choi, et al.. (2016). Thyroid transcription factor FOXE1 interacts with ETS factor ELK1 to co-regulate TERT. Oncotarget. 7(52). 85948–85962. 15 indexed citations

O'Connor, K., Grant P. Parnell, Ellis Patrick, et al.. (2013). Hepatic metallothionein expression in chronic hepatitis C virus infection is IFNL3 genotype-dependent. Genes and Immunity. 15(2). 88–94. 20 indexed citations

O'Connor, K. & Chris Liddle. (2013). Prospective data collection of off‐label use of rituximab in Australian public hospitals. Internal Medicine Journal. 43(8). 863–870. 16 indexed citations

Klümpen, Heinz‐Josef, Karel Eechoute, Mark Hertzberg, et al.. (2010). Pharmacogenetic factors predicting the need for a higher dose of imatinib.. Journal of Clinical Oncology. 28(15_suppl). 3098–3098. 1 indexed citations

Hilmer, Sarah N., et al.. (2009). Do medical courses adequately prepare interns for safe and effective prescribing in New South Wales public hospitals?. Internal Medicine Journal. 39(7). 428–434. 42 indexed citations

Sharma, Raghwa, et al.. (2007). Evaluation of the off‐label usage of rituximab in a large teaching hospital in New South Wales. Internal Medicine Journal. 37(8). 569–571. 8 indexed citations

Esteban, Luis, Terrie‐Anne Cock, Susan J. Allison, et al.. (2005). Promoter-, cell-, and ligand-specific transactivation responses of the VDRB1 isoform. Biochemical and Biophysical Research Communications. 334(1). 9–15. 14 indexed citations

Kumar, Dinesh, Craig T. Wallington‐Beddoe, Jacob George, et al.. (2003). Effectiveness of interferon alfa‐2b/ribavirin combination therapy for chronic hepatitis C in a clinic setting. The Medical Journal of Australia. 178(6). 267–271. 18 indexed citations

10.

Mistry, Prakash, Alistair Stewart, Wendy Dangerfield, et al.. (2002). In vitro and in vivo characterization of XR11576, a novel, orally active, dual inhibitor of topoisomerase I and II. Anti-Cancer Drugs. 13(1). 15–28. 50 indexed citations

11.

Vicker, Nigel, Irina Chuckowree, Adrian Folkes, et al.. (2002). Novel Angular Benzophenazines: Dual Topoisomerase I and Topoisomerase II Inhibitors as Potential Anticancer Agents. Journal of Medicinal Chemistry. 45(3). 721–739. 116 indexed citations

12.

Mistry, Prakash, Alistair Stewart, Wendy Dangerfield, et al.. (2001). In vitro and in vivo reversal of P-glycoprotein-mediated multidrug resistance by a novel potent modulator, XR9576.. PubMed. 61(2). 749–58. 302 indexed citations

13.

Farrell, Geoffrey C., Karen Byth, Rita Lin, et al.. (2000). Which patients with hepatitis C develop liver complications?. Hepatology. 31(2). 513–520. 135 indexed citations

14.

Ellis, Ewa, Bryan Goodwin, Anna Abrahamsson, et al.. (1998). Bile acid synthesis in primary cultures of rat and human hepatocytes. Hepatology. 27(2). 615–620. 41 indexed citations

15.

Farrell, GC, et al.. (1996). Increased hepatocyte CYP2E1 expression in a rat nutritional model of hepatic steatosis with inflammation. Gastroenterology. 111(6). 1645–1653. 340 indexed citations

16.

Williams, Stephen J., Philip I. Craig, Chris Liddle, Robert G Batey, & G C Farrell. (1987). HEPATITIS B IN AUSTRALIA: DETERMINANTS OF INTRAFANIILY SPREAD. Australian and New Zealand Journal of Medicine. 17(2). 220–227. 22 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact